Clinical Significance of Immune Cells and T-cell Subsets in Lung Cancer
DOI:
https://doi.org/10.37591/rrjoi.v9i2.1551Keywords:
lung cancer, immune T cells, inflammatory markers, flow cytometryAbstract
Objectives: The aim of the study was to determine the clinical usefulness of pretreatment hematological parameters including neutrophils, lymphocytes, monocytes and immune T-cell subsets as well as calculated coefficients such as neutrophils-to-lymphocytes ratio(NLR),monocytes-to-lymphocytes ratio(MLR) and platelets-to-lymphocyte ratio(PLR)in patients with lung cancer. Materials and Methods: A total of 102 patients with lung cancer were prospectively analyzed. T-cell subsets were assessed by flow cytometry method. Peripheral blood was collected from 25 healthy donors as control. The data were analyzed using SPSS software and p-value less than < 0.05 was considered statistically significant. Results: In comparison to healthy controls, neutrophils (P=0.0001), absolute neutrophils count (P=0.001), absolute monocyte count (P=0.0001), NLR (P=0.055), MLR (P=0.005) and PLR (P=0.047) was significantly higher while lymphocytes (P=0.0001) was significantly lower in lung cancer patient. Also, CD3+ T-cells (P=0.001), γδTCR (P=0.011), absolute T-cell count (P=0.0001), absolute helper T-cell count (P=0.0001) and absolute cytotoxic T-cell count (P=0.029) was found significantly lower in lung cancer patients. Conclusion: The present study observed neutrophilia, lymphocytopenia, and immune suppression reflect an imbalance in the immune response and contribute to lung carcinogenesis.
Keywords: lung cancer, immune T cells, inflammatory markers, flow cytometry
Cite this Article
Yadav DK, Modi H, Vora H. Clinical Significance of Immune Cells and T-cell Subsets in Lung Cancer. Research & Reviews: A Journal of Immunology. 2019; 9(2): 14–29p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |